Yoshiko Saito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshiko Saito has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hiroshi Ishikawa
Department of Obstetrics and Gynecology, Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
2 shared publications - Kaori Koga
Department of Obstetrics and Gynecology, Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
2 shared publications - Akiko Omoto
Department of Obstetrics and Gynecology, Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
1 shared publication - Ayako Okunaka
Department of Obstetrics and Gynecology, Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
1 shared publication H. Horiguchi
Kanagawa Univ
1 shared publication- Kiyotaka Kawai
Department of Reproductive Medicine, Kameda IVF Clinic Makuhari, Chiba, Japan
1 shared publication
Latest Publications
- Open Access
- 13 July 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Successful pregnancy following extensive myomectomy for diffuse uterine leiomyomatosis
Diffuse uterine leiomyomatosis (DUL) is a rare condition characterized by innumerable leiomyomas (fibroids) diffusely replacing the myometrium, often leadi
- 13 July 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessSuccessful pregnancy following extensive myomectomy for diffuse uterine leiomyomatosis
Diffuse uterine leiomyomatosis (DUL) is a rare condition characterized by innumerable leiomyomas (fibroids) diffusely replacing the myometrium, often leadi
- 5 September 2023
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 71 (4)
RISING STARS: Role of MED12 mutation in the pathogenesis of uterine fibroids
Graphical Uterine fibroids (UFs) are benign tumors arising from the uterus, characterized by accumulation of abundant extracellular matrix (ECM) and sex steroid-dependent growth. Women with symptomatic UFs have reduced quality of life and decreased labor productivity. Among the driver gene mutations identified in UFs, mutations in MED12, a component of the cyclin-dependent kinase (CDK) Mediator module, are the most common and observed in 50–80% of UFs. They are gain-of-function mutations and are more frequently observed in Black women and commonly observed even in small UFs. MED12 mutation-positive UFs (MED12-UFs) often develop multiple rather than solitary and have distinct gene expression profiles, DNA methylomes, transcriptomes, and proteomes. Gene expressions related to ECM organization and collagen-rich ECM components are upregulated, and impaired Mediator kinase activity and dysregulation of Wnt/β-catenin signaling are identified in MED12-UFs. Clinically, the UF shrinking effect of gonadotropin-releasing hormone agonists and ulipristal acetate is dependent on the MED12 mutation status. Understanding of characteristics of MED12-UFs and functions of MED12 mutations for UF tumorigenesis may elucidate the pathophysiology of UFs, leading to the development of new therapeutic options in women with symptomatic UFs.
- 5 September 2023
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 71 (4)
RISING STARS: Role of MED12 mutation in the pathogenesis of uterine fibroids
Graphical Uterine fibroids (UFs) are benign tumors arising from the uterus, characterized by accumulation of abundant extracellular matrix (ECM) and sex steroid-dependent growth. Women with symptomatic UFs have reduced quality of life and decreased labor productivity. Among the driver gene mutations identified in UFs, mutations in MED12, a component of the cyclin-dependent kinase (CDK) Mediator module, are the most common and observed in 50–80% of UFs. They are gain-of-function mutations and are more frequently observed in Black women and commonly observed even in small UFs. MED12 mutation-positive UFs (MED12-UFs) often develop multiple rather than solitary and have distinct gene expression profiles, DNA methylomes, transcriptomes, and proteomes. Gene expressions related to ECM organization and collagen-rich ECM components are upregulated, and impaired Mediator kinase activity and dysregulation of Wnt/β-catenin signaling are identified in MED12-UFs. Clinically, the UF shrinking effect of gonadotropin-releasing hormone agonists and ulipristal acetate is dependent on the MED12 mutation status. Understanding of characteristics of MED12-UFs and functions of MED12 mutations for UF tumorigenesis may elucidate the pathophysiology of UFs, leading to the development of new therapeutic options in women with symptomatic UFs.
- 1 January 1991
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 45 (2-3) , 87-93
Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia
- 1 January 1991
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 45 (2-3) , 87-93
Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia